Tahtis 2012.

Methods	Study design: RCT Number of dropouts: not stated Number of adverse effects: none Deaths: not stated ITT: unclear
Participants	Country: not stated 14 subacute stroke patients (2 to 8 weeks after stroke) Inclusion criteria: mobile stroke survivors with focal, ischaemic stroke; walking difficulties after stroke (self reported) Exclusion criteria: previous neurological conditions, seizure; musculoskeletal insult; pacemaker
Interventions	2 arms Dual‐tDCS with the anode placed over M1 of the lesioned hemisphere and the cathode placed over M1 of the non‐lesioned hemisphere (2 mA for 15 minutes) Sham tDCS with the anode placed over M1 of the lesioned hemisphere and the cathode placed over M1 of the non‐lesioned hemisphere (2 mA for < 30 seconds)
Outcomes	Outcomes were measured at baseline and at study end Performance Oriented Mobility Assessment TUG Tinnetti Balance and Gait Index
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Subjects were randomised to either the treatment group or to placebo"
Allocation concealment (selection bias)	Unclear risk	Not described by the authors
Blinding of participants and personnel (performance bias) Subjective outcome measures	Unclear risk	Participants were blinded, whereas blinding of personnel was not stated
Blinding of participants and personnel (performance bias) Objective outcome measures	Low risk	Participants were blinded, whereas blinding of personnel was not stated
Blinding of outcome assessment (detection bias) Subjective outcome measures	Low risk	Outcome assessors were blinded; quote: "Two independent assessors blindly assessed the POMA" and "Three consecutive recordings of the TUG were taken by the same blinded assessor"
Blinding of outcome assessment (detection bias) Objective outcome measures	Low risk	Outcome assessors were blinded; quote: "Two independent assessors blindly assessed the POMA" and "Three consecutive recordings of the TUG were taken by the same blinded assessor"
Incomplete outcome data (attrition bias) Subjective outcome measures	Unclear risk	All participants apparently completed the study. No treatment withdrawals, no losses to follow‐up, no trial group changes and no major adverse events were stated
Incomplete outcome data (attrition bias) Objective outcome measures	Unclear risk	All participants apparently completed the study. No treatment withdrawals, no losses to follow‐up, no trial group changes and no major adverse events were stated
Selective reporting (reporting bias)	Unclear risk	All outcomes reported in the methods section reported